Cannabinoids as Emergent Therapy Against COVID-19

Cannabis Cannabinoid Res. 2022 Oct;7(5):582-590. doi: 10.1089/can.2022.0018. Epub 2022 May 5.

Abstract

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory distress syndrome coronavirus 2 (SARS-Cov-2), was identified for the first time in late 2019 in China, resulting in a global pandemic of massive impact. Despite a fast development and implementation of vaccination strategies, and the scouting of several pharmacological treatments, alternative effective treatments are still needed. In this regard, cannabinoids represent a promising approach because they have been proven to exhibit several immunomodulatory, anti-inflammatory, and antiviral properties in COVID-19 disease models and related pathological conditions. This mini-review aims at providing a practical brief overview of the potential applications of cannabinoids so far identified for the treatment and prevention of COVID-19, finally considering key aspects related to their technological and clinical implementation.

Keywords: COVID-19; acute respiratory distress syndrome; antiviral; cannabinoid; cytokine storm.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Cannabinoids* / pharmacology
  • Humans
  • SARS-CoV-2

Substances

  • Cannabinoids
  • Antiviral Agents
  • Anti-Inflammatory Agents